Tata 1mg Achieves Profit Milestone with Digital Healthcare Expansion

Tata 1mg, a major player in India's digital healthcare sector, has announced it achieved EBITDA positivity across all its major operations in the fiscal year 2026. This profitability milestone marks a pivotal point for the company as it continues to expand its pharmacy, diagnostics, and specialty care services.

The company's diagnostics division reported an annualized revenue exceeding Rs 600 crore, driven by over 40% growth year-on-year, while maintaining double-digit EBITDA margins. Tata 1mg operates 19 NABL-accredited labs across 70 cities, with its National Reference Lab having College of American Pathologists accreditation.

The ePharmacy business, ranked as the leading service in India, reached breakeven, expanding its rapid medicine delivery within 10 cities. Additionally, the Speciality Pharma segment, which includes patient support, vaccinations, and cancer care, grew by approximately 65% in FY26.

Tata 1mg's strategy includes enhancing offline retail outlets to over 500 stores within a year and investing heavily in AI-led healthcare. Its AI platform, Pulse, is utilized by over 75 pharmaceutical companies, reflecting the company's growing influence as a health intelligence provider.

Looking ahead, Tata 1mg aims to focus on quicker pharmacy distribution, broaden diagnostics into radiology, establish partnerships in specialized care, and prioritize AI-driven personalization for continued growth and innovation into FY27 and beyond.

(With inputs from agencies.)